Close Menu

NEW YORK – Singapore-based AUM Biosciences and China-based Newsoara Biopharma on Wednesday announced that they had entered into a five-year strategic collaboration to develop up to six agents in AUM's pipeline, which consists of cancer therapies targeting critical biological pathways.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.